P A Cascales-Campos1,2, V López-López3,4, J Torres-Melero5, A Arjona6, F C Muñoz-Casares6,7, P Barrios8, R Morales9, F Pereira10, P Bretcha-Boix11, L González-Bayón12, S González-Moreno13, J Gil3,4. 1. Hospital Clínico, Universitario Virgen De La Arrixaca, Carretera Madrid-Cartagena S/N, El Palmar, CP: 30120, Murcia, Spain. cascalescirugia@gmail.com. 2. IMIB-Arrixaca, Murcia, Spain. cascalescirugia@gmail.com. 3. Hospital Clínico, Universitario Virgen De La Arrixaca, Carretera Madrid-Cartagena S/N, El Palmar, CP: 30120, Murcia, Spain. 4. IMIB-Arrixaca, Murcia, Spain. 5. Hospital Universitario De Torrecárdenas, Almería, Andalucia, Spain. 6. Hospital Universitario Reina Sofía, Córdoba, Andalucia, Spain. 7. Hospital Universtiario Virgen del Rocio, Sevilla, Spain. 8. Hospital De Sant Joan De Espi Moises Broggi, Sant Joan De Espi, Cataluña, Spain. 9. Hospital Universitario Son Espases, Palma de Mayorca, Islas Baleares, Spain. 10. Hospital Universitario De Fuenlabrada, Madrid, Spain. 11. Hospital Quirón de Torrevieja, Alicante, Comunidad Valenciana, Spain. 12. Hospital General Universitario Gregorio Marañón, Madrid, Spain. 13. MD Anderson Cancer Center, Madrid, Spain.
Abstract
BACKGROUND: The attitude toward cytoreductive surgery with HIPEC in peritoneal carcinomatosis from colorectal cancer is unclear. The aim of this study is to report the perioperative outcomes after cytoreductive surgery with HIPEC in patients ≥ 75 years. METHODS: This retrospective multicenter study collected the data the Spanish Group of Peritoneal Cancer Surgery. Thirty-six patients with peritoneal carcinomatosis from colorectal cancer met the selection criteria for the study. Morbidity, mortality, disease-free and overall survival were analyzed. RESULTS: Morbidity (grade III-IV) was 17% and 2 patients died of complications related to the procedure (5.4%). Median disease-free survival (DFS) was 16 months. DFS at 1 and 3 years was 81% and 42%, respectively. Overall survival at 1 and 3 years was 96% and 75%. In the univariate analysis, preoperative comorbidities (p = 0.01), liver metastases (p = 0.02), blood transfusion (p = 0.001) and postoperative complications (p = 0.001); and in the multivariate analysis, perioperative blood transfusion (OR 2.56, 95% CI 1.95-6.24, p = 0.03) and postoperative complications (OR 3.25, 95% CI 2.35-7.56, p = 0.02) were associated with a lower overall survival. CONCLUSIONS: Age is not an absolute contraindication to perform cytoreduction surgery with HIPEC in highly selected elderly patients with colorectal peritoneal carcinomatosis.
BACKGROUND: The attitude toward cytoreductive surgery with HIPEC in peritoneal carcinomatosis from colorectal cancer is unclear. The aim of this study is to report the perioperative outcomes after cytoreductive surgery with HIPEC in patients ≥ 75 years. METHODS: This retrospective multicenter study collected the data the Spanish Group of Peritoneal Cancer Surgery. Thirty-six patients with peritoneal carcinomatosis from colorectal cancer met the selection criteria for the study. Morbidity, mortality, disease-free and overall survival were analyzed. RESULTS: Morbidity (grade III-IV) was 17% and 2 patients died of complications related to the procedure (5.4%). Median disease-free survival (DFS) was 16 months. DFS at 1 and 3 years was 81% and 42%, respectively. Overall survival at 1 and 3 years was 96% and 75%. In the univariate analysis, preoperative comorbidities (p = 0.01), liver metastases (p = 0.02), blood transfusion (p = 0.001) and postoperative complications (p = 0.001); and in the multivariate analysis, perioperative blood transfusion (OR 2.56, 95% CI 1.95-6.24, p = 0.03) and postoperative complications (OR 3.25, 95% CI 2.35-7.56, p = 0.02) were associated with a lower overall survival. CONCLUSIONS: Age is not an absolute contraindication to perform cytoreduction surgery with HIPEC in highly selected elderly patients with colorectal peritoneal carcinomatosis.
Authors: Jesus Esquivel; Andrew M Lowy; Maurie Markman; Terence Chua; Joerg Pelz; Dario Baratti; Joel M Baumgartner; Richard Berri; Pedro Bretcha-Boix; Marcello Deraco; Guillermo Flores-Ayala; Olivier Glehen; Alberto Gomez-Portilla; Santiago González-Moreno; Martin Goodman; Evgenia Halkia; Shigeki Kusamura; Mecker Moller; Guillaume Passot; Marc Pocard; George Salti; Armando Sardi; Maheswari Senthil; John Spilioitis; Juan Torres-Melero; Kiran Turaga; Richard Trout Journal: Ann Surg Oncol Date: 2014-05-23 Impact factor: 5.344
Authors: V López-López; P A Cascales-Campos; M A Schneider; J Gil; E Gil; N Rodriguez Gomez-Hidalgo; P Parrilla Journal: Surg Oncol Date: 2016-09-07 Impact factor: 3.279
Authors: Vic J Verwaal; Serge van Ruth; Eeclo de Bree; Gooike W van Sloothen; Harm van Tinteren; Henk Boot; Frans A N Zoetmulder Journal: J Clin Oncol Date: 2003-10-15 Impact factor: 44.544
Authors: O Glehen; F Kwiatkowski; P H Sugarbaker; D Elias; E A Levine; M De Simone; R Barone; Y Yonemura; F Cavaliere; F Quenet; M Gutman; A A K Tentes; G Lorimier; J L Bernard; J M Bereder; J Porcheron; A Gomez-Portilla; P Shen; M Deraco; P Rat Journal: J Clin Oncol Date: 2004-08-15 Impact factor: 44.544
Authors: Konstantinos I Votanopoulos; Naeem A Newman; Greg Russell; Chukwuemeka Ihemelandu; Perry Shen; John H Stewart; Edward A Levine Journal: Ann Surg Oncol Date: 2013-06-19 Impact factor: 5.344